Form 8-K - Current report:
SEC Accession No. 0001628280-26-011971
Filing Date
2026-02-26
Accepted
2026-02-26 07:09:49
Documents
14
Period of Report
2026-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cccc-20260226.htm   iXBRL 8-K 29250
2 EX-99.1 cccc-20260226xexx991.htm EX-99.1 70029
6 c4tlogo1.jpg GRAPHIC 8913
  Complete submission text file 0001628280-26-011971.txt   241350

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cccc-20260226.xsd EX-101.SCH 1829
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cccc-20260226_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cccc-20260226_pre.xml EX-101.PRE 13088
16 EXTRACTED XBRL INSTANCE DOCUMENT cccc-20260226_htm.xml XML 2915
Mailing Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY SUITE 120 WATERTOWN MA 02472 (617) 231-0700
C4 Therapeutics, Inc. (Filer) CIK: 0001662579 (see all company filings)

EIN.: 475617627 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39567 | Film No.: 26681683
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)